Esperite N.V. (ESP): Sale by Esperite of stake in Cryo-Save South Africa cancelled
Amsterdam, The Netherlands – 03 October 2018
read more
ESPERITE (“Esperite N.V. (Euronext: ESP, “ESPERITE” or “the Company”) strengthens market position of Genoma with acquisitions of exclusive technologies for fully-certified groundbreaking genetic tests.
Stem cell historical CryoSave’s core business now profitable and improving.
Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results.
Zutphen, The Netherlands – 17 March 2015
ESPERITE (Esperite NV, (Euronext : ESP) « Esperite » ou « la Société ») renforce le positionnement de Genoma sur le marché par des acquisitions de technologies exclusives pour la réalisation de tests génétiques révolutionnaires entièrement certifiés.
Le coeur de métier historique de CryoSave dans les cellules souches est maintenant rentable et en constante amélioration.
Opérations consolidées, effectifs rationalisés, stratégies vente et marketing alignées, laboratoires intégrés, et processus automatisés pour l’obtention de meilleures performances et résultats.
Zutphen, Hollande – 17 Mars 2015
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that the extraordinary general meeting of shareholders (“EGM”) scheduled for 9 September 2013, that was convened by the company’s minority shareholder Salveo Holding S.A. (“Salveo”) in breach of the 180-day response time that Cryo-Save’s board of directors invoked, has been adjourned by court order.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that it has taken notice of the fact that Salveo Holding S.A. (‘Salveo’), the company’s minority shareholder with 27%, has convened an extraordinary general meeting of shareholders (‘EGM’) that shall be proposed to resolve on the appointment of a new executive director (CEO) and the replacement of one non-executive director.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces today that it has been presented with the outlines of the proposition of Salveo Holding S.A (‘Salveo’), the company’s major shareholder, underlying its request to convene an extraordinary general meeting of shareholders (‘EGM’) that shall be proposed to resolve on the appointment of a new CEO and the replacement of one non-executive director.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces further to its press release dated 15 May and as a matter of update of matters regarding Salveo Holding S.A. (‘Salveo’), Cryo-Save’s new 27 % shareholder, that it has received a request by Salveo to convene an extraordinary general meeting of shareholders.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that all proposed resolutions at today’s AGM were passed, except for the proposal to cancel the shares currently held in treasury.
Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that via a block-trade Mr Johan Goossens, Chairman, sold 900,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) to Salveo Holding SA on 7 May 2013 and that at the same day Mr Marc Waeterschoot, co-founder and former Board Member of Cryo-Save, via a block-trade sold 1,460,000 Ordinary Shares to Salveo Holding SA, both at a price of €1.70. Salveo Holding SA has not contacted management of Cryo-Save about its intentions as a major shareholder.
